Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
作者： Clara Montagut , Alba Dalmases , Beatriz Bellosillo , Marta Crespo , Silvia Pairet
DOI: 10.1038/NM.2609
关键词:
摘要: … Viability and EGFR signaling in the DCR clones were effectively decreased by treatment … (DCR) cells and treatment with cetuximab had this effect only in the parental but not in the DCR …
nature.com
mpg.de
core.ac.uk
sci-hub.se 参考文章(7)
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D'Haens, Tamás Pintér, Robert Lim, György Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 360, pp. 1408- 1417 ,(2009) , 10.1056/NEJMOA0805019
Jean-Yves Douillard, Salvatore Siena, James Cassidy, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, György Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocákova, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean-Luc Canon, Mark Rother, Kelly S Oliner, Michael Wolf, Jennifer Gansert, None, Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study Journal of Clinical Oncology. ,vol. 28, pp. 4697- 4705 ,(2010) , 10.1200/JCO.2009.27.4860
Marc Peeters, Timothy Jay Price, Andrés Cervantes, Alberto F. Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew H. Strickland, Gregory Wilson, Tudor-Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Valentina Tzekova, Simon Collins, Kelly S. Oliner, Alan Rong, Jennifer Gansert, Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 28, pp. 4706- 4713 ,(2010) , 10.1200/JCO.2009.27.6055
Rafael G. Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J. Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky, Scott D. Patterson, David D. Chang, Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 26, pp. 1626- 1634 ,(2008) , 10.1200/JCO.2007.14.7116
Muhammad Wasif Saif, Kristin Kaley, Edward Chu, M. Sitki Copur, Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clinical Colorectal Cancer. ,vol. 9, pp. 315- 318 ,(2010) , 10.3816/CCC.2010.N.046
Carsten Bokemeyer, Igor Bondarenko, Anatoly Makhson, Joerg T. Hartmann, Jorge Aparicio, Filippo de Braud, Serban Donea, Heinz Ludwig, Gunter Schuch, Christopher Stroh, Anja H. Loos, Angela Zubel, Piotr Koralewski, Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 663- 671 ,(2009) , 10.1200/JCO.2008.20.8397
Christos S. Karapetis, Shirin Khambata-Ford, Derek J. Jonker, Chris J. O'Callaghan, Dongsheng Tu, Niall C. Tebbutt, R. John Simes, Haji Chalchal, Jeremy D. Shapiro, Sonia Robitaille, Timothy J. Price, Lois Shepherd, Heather-Jane Au, Christiane Langer, Malcolm J. Moore, John R. Zalcberg, K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England Journal of Medicine. ,vol. 359, pp. 1757- 1765 ,(2008) , 10.1056/NEJMOA0804385